Abstract
90MO Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have